Infusion Providers Alliance Applauds Reintroduction of “The Protecting Patient Access to Cancer and Complex Therapies Act”

July 9, 2025

The Infusion Providers Alliance (IPA), which represents nearly 1,000 infusion centers across 43 states applauds Congressmen Greg Murphy (R-NC), Adam Gray (D-CA) and Neal Dunn (R-FL) for reintroducing the “Protecting Patient Access to Cancer and Complex Therapies Act,” which protects patients and their providers from collateral damage in the Medicare drug price negotiation program between the Secretary of the U.S. Department of Health and Human Services (HHS) and manufacturers.

Doug Ghertner, President of the Infusion Providers Alliance, issued the following statement today regarding the bipartisan reintroduction in the House of Representatives:

“IPA applauds Congressmen Greg Murphy, Adam Gray and Neal Dunn for reintroducing the ‘Protecting Patient Access to Cancer and Complex Therapies Act’ and their ongoing bipartisan leadership on this important issue. This critical legislation will ensure that patients with complex illnesses, such as multiple sclerosis, Crohn’s disease, rheumatoid arthritis and many orphan conditions, maintain access to their infused or injected medications to treat those conditions in IPA members convenient, community based, non-hospital settings.

“This legislation addresses an unintended consequence of the Inflation Reduction Act (IRA), which will significantly reduce physician reimbursement in the effort to lower drug prices. By protecting physician practices and infusion providers from steep cuts to their reimbursement for the administration of infusion drugs, Congress can ensure that it achieves its desired level of cost savings without compromising patient access.”

###

Background

Historically, Part B drugs have been paid on an average sales price (ASP)+6 percent methodology. The 6 percent add-on payment (reduced to 4.3% under sequester), is the key provider reimbursement component of these physician-administered drugs.

The Inflation Reduction Act requires the Secretary to negotiate the prices of the costliest drugs to Medicare. The Congressional Budget Office projects reimbursement reductions of 50 percent, including the add-on payment component related to provider reimbursement for drug administration of Part B drugs. Because the key aspect of reimbursement for drug administration is tied to the price of the drug through the “add-on” payment, policies that substantially reduce that add-on payment will have enormous negative ramifications on physicians and infusion facilities ability to provide those medications to patients.

The Protecting Patient Access to Cancer and Complex Therapies Act would replace those reimbursement reductions with an equivalent rebate paid by the pharmaceutical manufacturers that achieves the same amount of savings for the program while ensuring that Medicare beneficiaries can still take advantage of the lower negotiated rates and coinsurance resulting from the drug price negotiations. Importantly, the bill would maintain providers’ existing reimbursement and preserve patient access in these community-based settings, thereby ensuring that they do not become collateral damage as a result of the price reductions. A new analysis estimates the legislation would generate $3.3 billion in savings over 10 years because sequester would be applied to the ASP price rather than the lower “Maximum Fair Price” (MFP)+6 percent.

Previously, this legislation was endorsed by 58 patient and provider organizations including Infusion Providers Alliance (IPA), International Foundation for Autoimmune & Autoinflammatory Arthritis, American Academy of Allergy, Asthma, & Immunology (AAAAI), Association of Women in Rheumatology (AWIR), Cancer Support Network, Community Oncology Alliance (COA), Digestive Health Physicians Association (DHPA), and Large Urology Group Practice Association (LUGPA), among others.

About the Infusion Providers Alliance

The Infusion Providers Alliance (IPA) is committed to protecting the integrity of the provider-patient relationship by empowering providers and patients to choose the most appropriate treatment together. We advocate for policies that ensure timely and adequate patient access to high quality care in IPA members’ convenient, community-based, non-hospital settings. IPA members operate over 1,000 in-office or stand-alone ambulatory infusion centers across 43 states nationwide, delivering value to the health care system and improved outcomes to patients.

All inquiries should be emailed to ewarren@infusionprovidersalliance.org.